Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 8/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.53 |
| ▸ | CHRM4 | P08173 | 7/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.42 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23213409 | 0.91 | CHRM4 (0.50) | HTR1ASLC6A2SLC6A4SLC6A3CHRM4 | |
| SCHEMBL29619696 | 0.91 | CHRM4 (0.50) | HTR1ASLC6A2SLC6A4SLC6A3CHRM4 | |
| SCHEMBL23213411 | 0.91 | CHRM4 (0.50) | HTR1ASLC6A2SLC6A4SLC6A3CHRM4 | |
| SCHEMBL29619705 | 0.84 | CHRM4 (0.66) | CHRM4CHRM1CHRM2HTR2CMEN1 | |
| SCHEMBL29619706 | 0.84 | CHRM4 (0.66) | CHRM4CHRM1CHRM2HTR2CMEN1 | |
| SCHEMBL23213679 | 0.84 | CHRM4 (0.66) | CHRM4CHRM1CHRM2HTR2CMEN1 | |
| SCHEMBL23213674 | 0.84 | CHRM4 (0.66) | CHRM4CHRM1CHRM2HTR2CMEN1 | |
| SCHEMBL23213439 | 0.83 | CHRM1 (0.51) | HTR1ASLC6A2SLC6A4SLC6A3CHRM4 | |
| SCHEMBL23213442 | 0.83 | CHRM1 (0.51) | HTR1ASLC6A2SLC6A4SLC6A3CHRM4 | |
| SCHEMBL23213485 | 0.82 | CHRM4 (0.53) | HTR1ASLC6A2SLC6A4SLC6A3CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820778-B2 | 2-azaspiro[3.4]octane derivatives as M4 agonists | NOVARTIS AG (CH) | 2023-11-21 | — | — | US | disclosed |
| US-11820778-B2 | 2-azaspiro[3.4]octane derivatives as M4 agonists | NOVARTIS AG (CH) | 2023-11-21 | — | — | US | disclosed |
| US-20220411435-A1 | 2-AZASPIRO[3,4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-12-29 | — | — | US | disclosed |
| US-20210130365-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2021-05-06 | — | — | US | disclosed |
| WO-2021070091-A1 | 5-OXA-2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS AG (CH) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130365-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | CHRM2, CHRM1, CHRM3 | HTR1A 274/4885SLC6A2 1330/4885SLC6A4 1286/4885 |
| US-20220411435-A1 | 2-AZASPIRO[3,4]OCTANE DERIVATIVES AS M4 AGONISTS | CHRM2, CHRM1, CHRM3 | HTR1A 277/4885SLC6A2 1341/4885SLC6A4 1311/4885 |
| US-11820778-B2 | 2-azaspiro[3.4]octane derivatives as M4 agonists | CHRM2, CHRM1, CHRM3 | HTR1A 274/4885SLC6A2 1330/4885SLC6A4 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.